Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
An expert panel of 3 independent endocrinologists reviewed all reported thyroid-related laboratory abnormalities and AEs from the CARE-MS trials.
Over 6 years, 378 of 811 (47%) patients treated with alemtuzumab had a laboratory abnormality (n=36) or thyroid AE (n=342; 44 serious). A consensus on thyroid AEs was reached in 292 cases, adjudicated as follows:
- Graves’ disease: 40%;
- Hashimoto’s disease: 17%;
- transient thyroiditis: 8%;
- Graves’ disease switching to hypothyroidism 6%;
- Hashimoto’s disease switching to hyperthyroidism: 3%; and
- uncertain: 2%.
More than 97% of thyroid AEs were detected within 4 years of the last alemtuzumab course; 83% within 2 years. Patients with or without thyroid AEs received similar numbers of alemtuzumab courses. MS disease outcomes were similar in both groups in terms of annualised relapse rate, EDSS score change, brain volume loss, and being disease activity-free on MRI.
Treatment of thyroid AEs consisted of oral thyroid medications in 84%, primarily levothyroxine/levothyroxine sodium (64%) or thiamazole (43%). Another 11% underwent thyroidectomy, 9% had radioiodine therapy. At the most recent follow-up, cases were recovered (53%), ongoing (46%), or unknown (0.3%).
- Dayan C, et al. Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data. MSVirtual 2020, Abstract P0128.
Posted on
Previous Article
« Safety and efficacy of dimethyl fumarate: 13 years of follow-up Next Article
Management of progressive MS with approved DMT »
« Safety and efficacy of dimethyl fumarate: 13 years of follow-up Next Article
Management of progressive MS with approved DMT »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
November 25, 2020
Age and EDSS are risk factors for severe COVID-19
June 16, 2021
Tolebrutinib reduces brain lesions in very active MS
September 10, 2020
High NEDA rates after 2 years of ocrelizumab
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy